Aminologics Co.Ltd - Asset Resilience Ratio
Aminologics Co.Ltd (074430) has an Asset Resilience Ratio of 41.82% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Aminologics Co.Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Aminologics Co.Ltd's Asset Resilience Ratio has changed over time. See 074430 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Aminologics Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 074430 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩36.65 Billion | 41.82% |
| Total Liquid Assets | ₩36.65 Billion | 41.82% |
Asset Resilience Insights
- Very High Liquidity: Aminologics Co.Ltd maintains exceptional liquid asset reserves at 41.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aminologics Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Aminologics Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 65.38% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
Kolon Life Science Inc
KQ:102940 |
Pharmaceuticals | 1.22% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
Annual Asset Resilience Ratio for Aminologics Co.Ltd (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Aminologics Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.45% | ₩36.58 Billion ≈ $24.79 Million |
₩84.18 Billion ≈ $57.05 Million |
-18.85pp |
| 2024-12-31 | 62.30% | ₩35.38 Billion ≈ $23.98 Million |
₩56.79 Billion ≈ $38.49 Million |
+12.89pp |
| 2023-12-31 | 49.42% | ₩28.50 Billion ≈ $19.31 Million |
₩57.67 Billion ≈ $39.08 Million |
-3.19pp |
| 2022-12-31 | 52.60% | ₩29.24 Billion ≈ $19.81 Million |
₩55.58 Billion ≈ $37.67 Million |
+13.27pp |
| 2021-12-31 | 39.34% | ₩25.66 Billion ≈ $17.39 Million |
₩65.24 Billion ≈ $44.21 Million |
-2.88pp |
| 2020-12-31 | 42.21% | ₩25.38 Billion ≈ $17.20 Million |
₩60.13 Billion ≈ $40.75 Million |
-0.61pp |
| 2019-12-31 | 42.83% | ₩24.74 Billion ≈ $16.77 Million |
₩57.77 Billion ≈ $39.15 Million |
+4.33pp |
| 2018-12-31 | 38.50% | ₩21.89 Billion ≈ $14.83 Million |
₩56.86 Billion ≈ $38.53 Million |
+2.98pp |
| 2017-12-31 | 35.51% | ₩17.53 Billion ≈ $11.88 Million |
₩49.37 Billion ≈ $33.46 Million |
+5.55pp |
| 2016-12-31 | 29.96% | ₩14.69 Billion ≈ $9.96 Million |
₩49.03 Billion ≈ $33.22 Million |
+29.96pp |
| 2015-12-31 | 0.00% | ₩-220.00 ≈ $-0.15 |
₩55.03 Billion ≈ $37.29 Million |
-0.06pp |
| 2014-12-31 | 0.06% | ₩21.34 Million ≈ $14.46K |
₩38.63 Billion ≈ $26.18 Million |
-0.55pp |
| 2013-12-31 | 0.60% | ₩289.85 Million ≈ $196.43K |
₩48.20 Billion ≈ $32.67 Million |
-12.78pp |
| 2012-12-31 | 13.38% | ₩7.05 Billion ≈ $4.78 Million |
₩52.70 Billion ≈ $35.71 Million |
-14.27pp |
| 2011-12-31 | 27.65% | ₩23.28 Billion ≈ $15.77 Million |
₩84.17 Billion ≈ $57.04 Million |
+8.19pp |
| 2010-12-31 | 19.46% | ₩11.45 Billion ≈ $7.76 Million |
₩58.86 Billion ≈ $39.89 Million |
+11.68pp |
| 2008-12-31 | 7.78% | ₩5.15 Billion ≈ $3.49 Million |
₩66.21 Billion ≈ $44.87 Million |
-- |
About Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more